jump to content jump to footer

Comparison of iRECIST and RECIST 1.1 for Evaluating Immunotherapy in Melanoma and Non-Small Cell Lung Cancer

In a retrospective study conducted at the University Hospital Cologne, the radiological criteria iRECIST and RECIST 1.1 were compared for assessing treatment response in melanoma and NSCLC patients receiving immune checkpoint inhibitors.

The results indicate that iRECIST is better suited for capturing atypical treatment responses to immunotherapies, especially in patients experiencing pseudoprogression. iRECIST could thus contribute to a more accurate evaluation of treatment response and improved immunotherapy outcomes.

Read more about the study here.

Mint Medical and Coreline teams coming together to announce partnership
Mint Medical and Coreline Soft integrate AVIEW into mint Lesion to support AI-enabled workflows for structured reporting, Lung-RADS assessment, and longitudinal nodule management in lung cancer screening.
Coreline Soft and Mint Medical Announce Partnership to Advance AI-Enabled Lung Cancer Screening
Coreline Soft and Mint Medical today announced a partnership to advance AI-enabled lung cancer screening, following more than six months of technical…
Read more
Integrated prostate cancer workflow connecting radiology, urology, and pathology through structured reporting, MRI-guided biopsy, longitudinal follow-up, and AI-supported analysis.
mint Lesion supports an end-to-end prostate cancer workflow by connecting radiology, urology, and pathology within a unified digital environment. The platform enables structured mpMRI reporting, MRI/ultrasound fusion biopsy workflows, FHIR-based interoperability, active surveillance, and AI-supported quantification of metastatic disease.
Be Central to the Insight: A Structured, Data-Driven Approach to the End-to-End Prostate Pathway
Digital Integration for Multidisciplinary Teams  In the complex journey of prostate cancer diagnostics, the data contributed by every department is…
Read more
Research poster presentation on standardized tumor response assessments using mint Lesion at the NCCN Annual Conference 2026
Presentation of a research poster by Memorial Sloan Kettering Cancer Center on the use of mint Lesion for structured tumor response assessments and clinical research workflows.
NCCN 2026: Memorial Sloan Kettering Cancer Center Presents Research on Structured Tumor Response Assessments with mint Lesion
Big congratulations to Steven Philemond and Alison Chiaramonte of Memorial Sloan Kettering Cancer Center for presenting their research poster “Use of…
Read more
scroll-top